Katherine Zybach1, Craig A Friesen1, Jennifer V Schurman1. 1. Katherine Zybach, Craig A Friesen, Division of Gastroenterology, Hepatology and Nutrition, Children's Mercy Kansas City, Kansas City, MO 64108, United States.
Abstract
AIM: To study the effectiveness of melatonin vs placebo in children with functional dyspepsia (FD). METHODS: The study was conducted as a double blind, randomized, placebo controlled crossover trial. Subjects were aged 8-17 years and diagnosed with FD based on Rome III criteria. All subjects had failed to respond to 4 wk of acid suppression. Subjects receive a continuous two weeks of placebo and a continuous two weeks of melatonin in an order blinded to the participant and the study team. A Global Clinical Score was obtained to assess changes in abdominal pain. Pain was self-reported to be worse (grade 1), no change (grade 2), moderate improvement (grade 3), good (grade 4; minimal pain and not interfering with daily activities), or excellent (grade 5; no pain), respectively. A positive clinical response was defined as a grade 3 or greater response. Subjects wore an actigraph to assess sleep during a one week baseline period and during each treatment period. Subjects' sleep latency and total sleep time were recorded throughout the duration of the study. RESULTS:Fourteen subjects were enrolled and 12 completed the study. One withdrew prior to starting both melatonin and placebo and the other before starting melatonin. A positive clinical response (grade 3-5) was achieved in 42% of subjects on melatonin vs 50% of subjects on placebo (NS). Effect size was calculated and revealed a Cohen's D of 0.343 which demonstrates a medium effect favoring placebo. A grade 4 or grade 5 response was seen in 4 patients on melatonin and 5 patients on placebo. Baseline sleep parameters were in the healthy range with the longest sleep latency being just over 20 min (mean 7.46 ± 8.53 min) and the shortest sleep duration just over 7 h (mean 10.09 ± 2.72 h). The mean latency did not differ between periods of treatment with melatonin as compared to placebo (4.48 ± 6.45 min vs 3.58 ± 4.24 min; NS). The mean sleep duration did not differ between periods of treatment with melatonin as compared to placebo (9.90 ± 3.53 h vs 9.41 ± 2.70 h; NS). CONCLUSION:Melatonin does not appear to have efficacy in relieving pain in unselected pediatric FD. Future studies should consider FD subtypes, pathophysiologic mechanisms, and baseline sleep disturbances.
RCT Entities:
AIM: To study the effectiveness of melatonin vs placebo in children with functional dyspepsia (FD). METHODS: The study was conducted as a double blind, randomized, placebo controlled crossover trial. Subjects were aged 8-17 years and diagnosed with FD based on Rome III criteria. All subjects had failed to respond to 4 wk of acid suppression. Subjects receive a continuous two weeks of placebo and a continuous two weeks of melatonin in an order blinded to the participant and the study team. A Global Clinical Score was obtained to assess changes in abdominal pain. Pain was self-reported to be worse (grade 1), no change (grade 2), moderate improvement (grade 3), good (grade 4; minimal pain and not interfering with daily activities), or excellent (grade 5; no pain), respectively. A positive clinical response was defined as a grade 3 or greater response. Subjects wore an actigraph to assess sleep during a one week baseline period and during each treatment period. Subjects' sleep latency and total sleep time were recorded throughout the duration of the study. RESULTS: Fourteen subjects were enrolled and 12 completed the study. One withdrew prior to starting both melatonin and placebo and the other before starting melatonin. A positive clinical response (grade 3-5) was achieved in 42% of subjects on melatonin vs 50% of subjects on placebo (NS). Effect size was calculated and revealed a Cohen's D of 0.343 which demonstrates a medium effect favoring placebo. A grade 4 or grade 5 response was seen in 4 patients on melatonin and 5 patients on placebo. Baseline sleep parameters were in the healthy range with the longest sleep latency being just over 20 min (mean 7.46 ± 8.53 min) and the shortest sleep duration just over 7 h (mean 10.09 ± 2.72 h). The mean latency did not differ between periods of treatment with melatonin as compared to placebo (4.48 ± 6.45 min vs 3.58 ± 4.24 min; NS). The mean sleep duration did not differ between periods of treatment with melatonin as compared to placebo (9.90 ± 3.53 h vs 9.41 ± 2.70 h; NS). CONCLUSION:Melatonin does not appear to have efficacy in relieving pain in unselected pediatric FD. Future studies should consider FD subtypes, pathophysiologic mechanisms, and baseline sleep disturbances.
Authors: Nicola Cellini; Matthew P Buman; Elizabeth A McDevitt; Ashley A Ricker; Sara C Mednick Journal: Chronobiol Int Date: 2013-05-30 Impact factor: 2.877
Authors: John M Rosen; Jose T Cocjin; Jennifer V Schurman; Jennifer M Colombo; Craig A Friesen Journal: World J Gastrointest Pharmacol Ther Date: 2014-08-06
Authors: M D Maldonado; M Mora-Santos; L Naji; M P Carrascosa-Salmoral; M C Naranjo; J R Calvo Journal: Pharmacol Res Date: 2009-12-04 Impact factor: 7.658
Authors: Jennifer Verrill Schurman; Craig A Friesen; Hongying Dai; Caroline Elder Danda; Paul E Hyman; Jose T Cocjin Journal: BMC Gastroenterol Date: 2012-10-15 Impact factor: 3.067
Authors: Alice E Martin; Tamsin V Newlove-Delgado; Rebecca A Abbott; Alison Bethel; Joanna Thompson-Coon; Rebecca Whear; Stuart Logan Journal: Cochrane Database Syst Rev Date: 2017-03-06
Authors: Maria Luísa Cordeiro Santos; Ronaldo Teixeira da Silva Júnior; Breno Bittencourt de Brito; Filipe Antônio França da Silva; Hanna Santos Marques; Vinícius Lima de Souza Gonçalves; Talita Costa Dos Santos; Carolina Ladeia Cirne; Natália Oliveira E Silva; Márcio Vasconcelos Oliveira; Fabrício Freire de Melo Journal: World J Clin Pediatr Date: 2022-03-09